Video
Author(s):
Anita Kumar, MD, discusses navigating CAR T-cell therapy–related toxicities in mantle cell lymphoma.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Anita Kumar, MD, medical oncologist, Regional Care Network Medical Site Director, MSK Basking Ridge, Memorial Sloan Kettering Cancer Center, discusses navigating CAR T-cell therapy–related toxicities in mantle cell lymphoma (MCL).
In MCL, treatment with the CAR T-cell therapy brexucabtagene autoleucel (brexu-cel; Tecartus) is associated with a risk of adverse effects, including cytokine release syndrome (CRS) and neurotoxicity, Kumar says. Findings from the phase 2 ZUMA-2 trial (NCT02601313), which data led to the July 2020 FDA approval of brexu-cel, revealed that 15% and 31% of patients developed grade 3 or higher CRS and neurotoxicity, respectively.
To mitigate the toxicity risk with brexu-cel, patients should be well selected, Kumar explains. Factors such as age, comorbidities, and disease status, including tumor burden and time of initial treatment, could be potential predictors for toxicity, Kumar says. As such, the field should work toward developing a greater understanding of how to select patients to optimize efficacy and quality of life, Kumar concludes.
Dr Meric-Bernstam on the Efficacy and Safety of Dato-DXd in Metastatic Urothelial Cancer
Orca-Q Shows Promise in High-Risk Hematologic Cancers and BFT Conditioning May Synergize With the Agent
Avelumab Maintenance Improves OS and PFS in Advanced Urothelial Carcinoma, Regardless of Diabetes Status
Obe-Cel Elicits High MRD-Negative Response Rates in R/R B-ALL
Cilta-Cel Provides Deep MRD Negativity in Lenalidomide-Refractory Multiple Myeloma
Orca-Q Shows Promise in High-Risk Hematologic Cancers and BFT Conditioning May Synergize With the Agent
Avelumab Maintenance Improves OS and PFS in Advanced Urothelial Carcinoma, Regardless of Diabetes Status
Obe-Cel Elicits High MRD-Negative Response Rates in R/R B-ALL
2 Commerce Drive
Cranbury, NJ 08512